Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients(SLAM) | withdrawn | Phase 1 / Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 0 | Jan 26, 2023 | clinicaltrials |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma(SCORE) | withdrawn | Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 1 |
| Jan 26, 2023 |
| clinicaltrials |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | withdrawn | Phase 2 | 0 | Attaya SuvannasankhaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04639843 | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05239910 | Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL | withdrawn | Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 1 | Oct 17, 2022 | clinicaltrials |
| NCT04635683 | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | withdrawn | Phase 1 | 0 | Yazeed SawalhaOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04998747 | A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ProxiMMity-1) | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 27, 2022 | clinicaltrials |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT04802031 | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Thomas Martin, MDOTHER | 0 | Jul 7, 2022 | clinicaltrials |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04836832 | Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 1 | 0 | Narendranath EpperlaOTHER | 0 | Jun 7, 2022 | clinicaltrials |
| NCT03660072 | Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03492268 | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | withdrawn | N/A | 0 | Bioray LaboratoriesINDUSTRY | 1 | May 17, 2022 | clinicaltrials |
| NCT04535102 | POLA+BR for Relapsed or Refractory DLBCL | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 0 | May 9, 2022 | clinicaltrials |
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma(ESdRRMM) | withdrawn | Phase 2 | 0 | Tulane University School of MedicineOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT04849715 | A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma(CITADEL-310) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT04361851 | Study of Dara-Pembro for Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT02847949 | A Study of IGN002 for Refractory NHL | withdrawn | Phase 1 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jan 24, 2022 | clinicaltrials |
| NCT02589860 | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant | withdrawn | — | 0 | Sherif S. FaragOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT04918511 | A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma(COAST) | withdrawn | Phase 1 | 0 | Oncopeptides ABINDUSTRY | 1 | Nov 26, 2021 | clinicaltrials |
| NCT03639324 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL(RIVe-CLL/SLL) | withdrawn | Phase 1 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation | withdrawn | Phase 1 | 0 | Medigene AGINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant(Immuno-POWER) | withdrawn | Phase 2 | 0 | Natalie CallendarOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | withdrawn | Phase 1 / Phase 2 | 0 | Gilead SciencesINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma(PLACARD) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Aug 17, 2021 | clinicaltrials |
| NCT04288765 | Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma | withdrawn | Phase 3 | 0 | Grupo Cooperativo de Hemopatías MalignasOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | withdrawn | N/A | 0 | Rochester General HospitalOTHER | 0 | Apr 27, 2021 | clinicaltrials |
| NCT03719898 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Jan 5, 2021 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT04621955 | Observational Study of Home Administration of Carfilzomib(KARE-2) | withdrawn | — | 0 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Nov 9, 2020 | clinicaltrials |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia | withdrawn | Phase 1 | 0 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | withdrawn | Phase 1 | 0 | National Cancer Centre, SingaporeOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | withdrawn | Phase 1 / Phase 2 | 0 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | withdrawn | — | 0 | George Washington UniversityOTHER | 1 | Oct 6, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jan 26, 2023source: clinicaltrials